Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03217643
Title CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. (EATL-001)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Imagine Institute

peripheral T-cell lymphoma


Brentuximab vedotin

Age Groups: senior | adult
Covered Countries FRA

No variant requirements are available.